OpenAI buys Orchestra Bio to streamline drug development with AI

OpenAI acquires Orchestra Bio

OpenAI has purchased Orchestra Bio, a San Francisco startup that uses AI agents to help pharmaceutical companies manage drug development schedules. The ChatGPT maker announced the deal on Tuesday, although financial terms were not disclosed. Orchestra’s team and platform will be integrated into Rosalind, OpenAI’s suite of AI tools designed for biologists and chemists.

Key numbers and facts

• Orchestra raised approximately $20 million in total funding, according to Caplight data.
• The company was founded in the fall of 2022.
• OpenAI states that bringing a new medicine to U.S. approval can take up to 15 years.
• The cost of bringing one approved drug to market is estimated to exceed $2.6 billion.

What the announcement says

In a statement, OpenAI said its goal is to help scientists make discoveries and manage the work required to turn them into treatments that reach patients sooner. The company explained that drug teams often struggle to coordinate work across different departments and external partners, such as contract research organizations and manufacturers. These groups frequently rely on systems that do not communicate effectively with one another.

How the AI agents work

Orchestra’s AI agents are software programs that monitor tasks and flag problems independently. They identify which activities and deadlines are affected by setbacks, such as a failed manufacturing batch. The agents gather relevant information and compare possible responses, but scientists and program leaders retain the final decision-making authority.

Context in the AI biotech race

This acquisition follows a similar move by rival Anthropic, which purchased Coefficient Bio for roughly $400 million in April. Anthropic also launched a research platform called Claude Science in June. OpenAI launched its own biology model, GPT-Rosalind, in April, restricting access to vetted U.S. enterprise customers. A companion product, Rosalind Workbench, connects the model to scientific tools and data. OpenAI has also recently acquired Torch, a records startup, for a reported $100 million and integrated a scientific writing tool called Crixet into its Prism platform.

Business model and future plans

OpenAI has indicated it seeks revenue sources beyond subscription fees. In a January blog post, CFO Sarah Friar wrote that as AI moves into drug discovery, the company expects to share in the value created through licensing, IP-based agreements, and outcome-based pricing. OpenAI did not specify when Orchestra’s agents will appear inside Rosalind, though it recently offered free seats to eligible U.S. university labs through a new academic plan.

Sources

• Decrypt